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doi:10.1Objective: Our objective was to perform a prospective randomized trial to evaluate the clinical and angiographic
outcomes of a second-generation anastomotic device used for saphenous vein grafts.
Methods: Patients undergoing nonemergency isolated coronary artery bypass grafting at 3 centers from August
2003 to December 2004 with at least 2 saphenous vein grafts were included. The proximal anastomoses were
randomized, within each patient, to be constructed by the connector or by suture. One-year graft patency was
evaluated by coronary angiography, magnetic resonance imaging, or computed tomography and analyzed on
an intent-to-treat basis.
Results: A total of 151 patients (65  9 years, 87% male) who met inclusion/exclusion criteria were enrolled in
the study and were analyzed. A total of 489 grafts were constructed (3.2  0.5 grafts per patient), including 327
vein grafts randomized to the connector (n¼ 162) or suture (n¼ 165). In 162 connector grafts, 151 devices were
successfully implanted. Technical issues required explantation of 11 devices intraoperatively. Patency was
evaluated in 120 (81%) patients with 260 study grafts. Seventy-four patients with 161 grafts were evaluated
by coronary angiography, 31 patients with 69 grafts by magnetic resonance imaging, and 15 patients with 30
grafts by computed tomography. The 1-year patency rate for study grafts constructed with the anastomotic con-
nector was 92.2% (118/128) and for hand-sutured grafts, 91.7% (121/132).
Conclusions: This prospective multicenter randomized controlled trial demonstrated good in-hospital and late
clinical outcomes and excellent 1-year patency for vein grafts anastomosed both by the St Jude Medical sec-
ond-generation aortic connector system and by hand. The patency of the connector grafts did not differ from
that of the hand-sutured grafts. (J Thorac Cardiovasc Surg 2010;139:741-7)SVascular anastomoses in coronary artery bypass grafting
(CABG) are usually performed with continuous sutures for
both proximal and distal anastomoses. Several years ago,
however, considerable interest arose in the development of
sutureless anastomotic devices for CABG, spurred in part
by increasing use of off-pump coronary artery bypass (OP-
CAB) and the desire to avoid aortic manipulation and the
side-biting clamp, as well as in their potential to facilitate
minimally invasive surgery. The introduction of the Symme-
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/BPaul, Minn) was associated with satisfactory short-term out-
comes,1-4 resulting in more than 40,000 implants worldwide.
Further investigation revealed no effect of the device and
delivery system on graft endothelial function5 and a 1-year
patency rate of 100% in grafts to the right coronary artery.5
There were, however, reports of complications such as
stenoses in the vein graft close to the connector site.6-8 There
were several issues with the first-generation Symmetry
device, one being the requirement for a 90 takeoff of the
saphenous vein graft from the aorta, resulting in a potential
risk of kinking if the proximal anastomosis was incorrectly
sited. Another issue was the need for introduction of
a transfer sheath into the vein graft, with at least the potential
for endothelial injury.9
So that these issues could be addressed, a second-genera-
tion device was developed that allowed angled anastomoses
and did not require instrumentation of the retained segment
of the vein graft. The aim of this multicenter prospective ran-
domized trial was to investigate the safety and efficacy of
this second-generation anastomotic connector system.METHODS
This study was approved by the local Ethics Committees of Sahlgrenska
University Hospital, Toronto General Hospital, and Ceske Budejovice
Hospital.rdiovascular Surgery c Volume 139, Number 3 741
FIGURE 1. Schema showing loading (A) and placement (B) of the St Jude
Medical second-generation aortic connector. A, The delivery system is
introduced through the proximal end of the graft, which will subsequently
be excluded. B, The device has hooks to engage the edges of the venotomy.
The system is oriented perpendicularly to the aortotomy. (Reprinted with per-
mission of the Cardiovascular Division, St Jude Medical, Inc, St Paul, Minn.)
FIGURE 2. Schema showing disengagement of the delivery system from
the deployed device (A) and final appearance of the proximal anastomosis
(B). The side-to-side anastomosis is followed by careful placement of
a clip to exclude the proximal segment of vein, rendering this into a function-
ally beveled anastomosis, and in which the endothelium of the retained vein
graft segment has not been in contact with the delivery system. (Reprinted
with permission of the Cardiovascular Division, St Jude Medical, Inc, St
Paul, Minn.)
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CT ¼ computed tomography
LITA ¼ left internal thoracic artery
MRI ¼ magnetic resonance imaging
OPCAB ¼ off-pump coronary artery bypass
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This randomized trial was performed at 3 centers from August 2003 to
December 2004. Patients undergoing elective or nonemergency isolated
on-pumpCABGwith at least 2 planned saphenous vein grafts were included
in the study. Exclusion criteria included the following: requirement for con-
comitant valve surgery, reoperative or emergency coronary surgery, OP-
CAB, minimally invasive vein harvesting, left ventricular ejection
fraction less than 25%, creatinine level greater than 2.0 mg/dL, current
smoker, pregnancy, and participation in other investigational protocols. Pa-
tients with saphenous veins that were too small or too large for the range of
devices were excluded intraoperatively from the study. Patient demograph-
ics, intraoperative data, hospital outcomes, and clinical follow-up data were
collected. Graft patency was assessed at 1 year by conventional contrast an-
giography, computed tomographic (CT) angiography, or magnetic reso-
nance imaging (MRI).
Operative Technique and Randomization
The operation was performed by conventional on-pump techniques, with
the use of a single crossclamp or side-biting clamp at the discretion of the
surgeon. Epiaortic echocardiography was used to confirm that there was
no significant aortic atherosclerosis at the proposed site of the proximal graft
anastomoses. After construction of one or more distal anastomoses, the vein
graft segments were cut to an appropriate length and the internal diameter of
the proximal end of the vein graft was measured with a sizing tool. The ap-
propriate size of the connector (3.0–4.5 mm internal diameter) for that vein
segment was recorded. Each graft/target vessel combination was assigned
a number by the surgeon. After this, the randomization envelope for each
graft number was opened. In this way, each proximal anastomosis was ran-
domized, within each patient, to be constructed by the connector or by su-
ture. Each patient received at least 1 connector graft and 1 hand-sutured
graft. In patients receiving 3 or more vein grafts, it was left to the surgeon’s
discretion whether the third or fourth vein grafts were randomized or were
performed in the standard fashion (and thus excluded from the comparative
analysis).
Intraoperative graft flow evaluations were performed with an 8-MHz
Doppler flow meter with a corresponding size of flow probe (Medi-Stim
Butterfly Flow Meter; Medi-Stim AS, Oslo, Norway) or by continuous-
wave Doppler sonography, according to usual practice at each institution.
All patients received acetylsalicylic acid postoperatively.
Design and Delivery of the St Jude Medical Second-
Generation Connector
The design and delivery technique have been described elsewhere.8,10 In
brief, the device is constructed of nitinol but was designed, in contrast to the
first-generation device, to create an anatomically side-to-side, but function-
ally beveled, anastomosis. The graft is loaded onto the delivery system
through the proximal end of the vein, which is then excluded from the graft
after completion of the anastomosis, so that there is no contact of the deliv-
ery system with the endothelium of the retained segment of vein (Figure 1).
After creation of the aortotomy and insertion of the connector, the connector
is deployed and the delivery system removed. The proximal vein graft
stump is ligated, with care taken not to create a residual stump (Figure 2).742 The Journal of Thoracic and Cardiovascular SurgFollow-up and Graft Assessment
Patients were followed up clinically at 6- and 12-month intervals. One
year postoperatively, patients underwent radiographic evaluation of graft
patency. For the majority of patients, this was carried out by contrast angi-
ography of the vein grafts; angiography of left internal thoracic artery
(LITA) and radial artery grafts was not mandated by the protocol. However,
in the latter portion of the study, graft evaluation was performed by CT an-
giography or MRI to eliminate the small but nontrivial risks associated with
contrast angiography. Graft patency and stenoses were evaluated by an in-
dependent core laboratory (PERFUSE Angiographic Core Laboratory and
Data Coordinating Center, Boston, Mass).
Statistical Analysis
Data are presented as mean  SD. Discrete data were subjected to c2
analyses, whereas continuous data were analyzed by the Student t test.
Graft-related outcomes were analyzed on an intent-to-treat basis.
RESULTS
Patients and Grafts
A total of 151 patients with a mean age of 65  9 years
who met study inclusion/exclusion criteria were enrolledery c March 2010
TABLE 1. Patient demographics
Variable (%)
All patients
(n ¼ 151)
Patients undergoing
graft evaluation (n ¼ 120)
Patients not undergoing
graft evaluation (n ¼ 31)
P value for 120 patients
vs 31 patients
Male 87 87 87 .9
Hypertension 63 63 65 .8
Hypercholesterolemia 64 64 61 .8
Previous TIA 3.3 4.2 0 .2
Previous CVA 2 1.7 3.2 .6
PVD 7.3 5.8 13 .2
Smoking history 60 58 71 .2
Diabetes 33 33 32 1.0
Renal failure 2.7 1.7 6.5 .1
Previous MI 54 57 45 .3
Congestive heart failure 4.6 5 3.2 .7
Angina 92 93 90 .7
Unstable angina 53 56 42 .2
CCS angina class .1
I 19 19 16
II 18 18 16
III 37 37 39
IV 24 24 23
NYHA functional class .9
I 47 48 31
II 24 24 45
III 13 13 23
IV 2 1.7 3.2
Previous PTCA 14 13 16 .7
Previous stent 6 5.8 6.5 .9
TIA, Transient ischemic attack; CVA, cerebrovascular accident; PVD, peripheral vascular disease;MI, myocardial infarction; CCS, Canadian Cardiovascular Society; NYHA, New
York Heart Association; PTCA, percutaneous transluminal coronary angioplasty.
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tailed in Table 1. A total of 489 grafts were constructed in
these patients (3.2  0.5 grafts per patient), including 327
vein grafts randomized to the connector (n ¼ 162) or suture
(n ¼ 165). There were also 140 LITA grafts, 2 radial artery
grafts, and 20 saphenous vein grafts that were not random-
ized (some patients had more than 2 vein grafts, but only 2
vein grafts were randomized).
Connector implantation. In 162 connector grafts, 151
(93.2%) devices were successfully implanted on the first at-
tempt. Technical problems, including excessive gathering of
the side walls of the vein graft causing a ‘‘seagull’’ defor-
mity of the hood of the graft, required explantation of 11 de-
vices intraoperatively. A second device was used in 6 of
these grafts, for a total successful connector implantation
rate of 96.9%, and the other 5 grafts were sutured.
In-hospital outcomes. There were 2 (1.3%) early deaths.
One death occurred in a 79-year-old man with insulin-de-
pendent diabetes and a left ventricular ejection fraction of
40%, in whom protamine administration after cardiopulmo-
nary bypass was associated with cardiovascular collapse and
in whom attempts at resuscitation were unsuccessful. The
other death occurred in an 83-year-old patient in whom the
initial connector deployment resulted in a visually obviousThe Journal of Thoracic and Camoderate stenosis at the proximal anastomosis. The connec-
tor was replaced with a second device without incident. The
hemodynamic course in this patient was unremarkable, but
both respiratory and dialysis-dependent renal failure devel-
oped. The family opted for palliative care rather than con-
tinuing dialysis, and the patient died several weeks after
hospital discharge.
Five (3.3%) patients underwent reoperation for bleeding,
including 1 patient who had re-exploration twice. In none of
these patients was a connector graft the source of bleeding.
No patient underwent reoperation for graft revision. Four
(2.6%) patients had strokes and 1 (0.7%) patient had a tran-
sient ischemic attack. One (0.7%) patient had a perioperative
myocardial infarction. Two (1.3%) patients had sternal oste-
omyelitis. Two (1.3%), patients had renal failure requiring
dialysis postoperatively, and another 2 (1.3%) had elevated
creatinine levels but did not require dialysis. Thirty-seven
(25%) patients had atrial fibrillation postoperatively.
Midterm outcomes. One (0.7%) patient, a 51-year-old
man with a left ventricular ejection fraction of 35% who
had had an uneventful hospital course, died 10 months post-
operatively. A postmortem examination demonstrated a pos-
terior myocardial infarction, with all 3 of the bypass grafts
patent.rdiovascular Surgery c Volume 139, Number 3 743
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up angiography. Because of this event, subsequent patients
were evaluated by CT angiography or MRI.
At 1 year, patients reported a mean Canadian Cardiovas-
cular Society angina class of 1.01  0.2.
Graft evaluation and patency. Patency was evaluated in
120 (81%) patients with 260 study grafts. Of the 120 pa-
tients returning for graft assessment, 74 patients with 161
grafts were evaluated by coronary angiography, 31 patients
with 69 grafts by MRI, and 15 patients with 30 grafts by CT.
Demographics and intraoperative variables for the 120 pa-
tients undergoing graft assessment versus the 31 patients
who did not are compared in Table 1. The mean interval
from surgery to angiographic/MRI/CT follow-up was 418
 83 days (13.9 months).
The 1-year patency rate for study grafts constructed with
the anastomotic connector was 92.2% (118/128) and for
hand-sutured grafts, 91.7% (121/132).
Analysis of various subgroups in the 120 patients under-
going graft evaluation demonstrated patency rates of 92.9%
(13/14 grafts) in nonrandomized saphenous vein grafts and
of 90% (9/10 grafts) in grafts randomized to the connector,
in which the first connector had to be explanted immediately
owing to technical issues. There were 113 LITA grafts in the
120 patients undergoing graft evaluation. The LITA was
evaluated in 78 of those patients, with an observed patency
rate of 96.2% (75/78).
Five (1.8%) nonocclusive stenoses were observed in the
274 vein grafts evaluated. There was 1 stenosis, of 50% se-
verity, in the distal portion of a sutured vein graft. There
were 4 (3.1%) stenoses, all ostial in location, in the 128 con-
nector grafts, ranging from 65% to 90% in severity. All 4 of
these patients were free of angina or reintervention at 1-year
follow-up.
DISCUSSION
This prospective randomized multicenter study demon-
strated excellent patency, at more than 1 year, of grafts in
which the proximal anastomoses were constructed with
a second-generation anastomotic connector. Patency rates
of conventional sutured grafts were similarly excellent.
Use of this second-generation device therefore had no dis-
cernible impact on midterm graft patency.
Rates of mortality and major morbidity were in line with
current expectations for CABG surgery. As our within-pa-
tient randomization scheme meant that all patients had
both connector and sutured grafts, it was not possible to com-
pare mortality and morbidity between connector and suture
groups. However, the 2 early deaths and 1 late death were
unrelated to the device, or apparently to the grafts at all,
and in the patients who underwent re-exploration for bleed-
ing, there was no bleeding from any connector anastomoses.
There were thus no significant safety issues identified with
use of the device. There were, however, 11 connectors that744 The Journal of Thoracic and Cardiovascular Surgwere explanted after initial deployment owing to technical
issues. Most of these issues occurred early in our experience.
The excellent patency rates of the second-generation con-
nector observed in this study contrast with some reports of
the experience with the first-generation Symmetry device.
Whereas patency rates of as high as 100% at 1 year have
been reported with first-generation connectors,5 stenoses in
the proximal segment of the vein graft, in proximity to the
connector, have been noted in 22% to 38%5,6 of grafts.
Others have noted significant rates of occlusion and reinter-
vention associated with the first-generation device.7,8
At least 3 theories have been advanced as potential rea-
sons for the higher-than-anticipated rates of proximal steno-
ses and occlusions in grafts in which the first-generation
device was used. Differences between the first- and sec-
ond-generation devices in these 3 aspects may therefore un-
derlie any observed differences in patency. First, the original
device created a 90 end-to-side anastomosis. Particularly
for left-sided grafts, it is easy to have a graft kinked proxi-
mally against the pericardium or mediastinal tissue, inas-
much as it does not adopt the usual course of a sutured
graft with a beveled anastomosis. This problem is accentu-
ated when proximal anastomoses are constructed with a par-
tial-occlusion clamp, inasmuch as they are moved more
anteriorly on the aorta. The second-generation device creates
an anatomically side-to-side but functionally beveled anas-
tomosis, avoiding this difficulty.
A second issue with the first-generation device was that its
delivery system required instrumentation, with a transfer
sheath, of the vein segment that was retained as a graft. Al-
though ex vivo experiments did not demonstrate an obvious
effect on endothelial function,5 it seems likely, particularly
with small vein segments that were pulled onto the transfer
sheath, that endothelial injury or denudation may have oc-
curred. The delivery system for the second-generation de-
vice is passed through the vein through its proximal end,
via a segment that is subsequently excluded with a clip.
Therefore, the vein segment functioning as a graft is never
instrumented and should not be subject to any additional en-
dothelial insult.
A third but perhaps less important issue was that proximal
anastomoses had to be constructed before distal anastomoses
when the first-generation connector was used. This is not the
usual order of anastomoses for most surgeons, and determi-
nation of the correct length of the vein, and avoidance of ten-
sion on the connector anastomosis, may be more difficult.
The second-generation device permits construction of distal
anastomoses before proximal anastomoses and thus requires
less deviation from the usual routine.
From a practical point of view, the loading process for the
second-generation device is also considerably simpler and
faster, requiring only 10 to 15 seconds, than that for the orig-
inal device. It is not as difficult to visually confirm that the
vein is properly loaded.ery c March 2010
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connector vein grafts was approximately 92%. This com-
pares favorably with other randomized trials in which vein
graft patency was evaluated, but as in most studies involving
novel intraoperative interventions and invasive follow up,
these were highly selected patients. Our patency rates may
have been influenced by our vein sizing criteria; only vein
segments with internal diameters between 3.0 and 4.5 mm
were used, excluding poor quality veins with varicosities
or severe phlebitis. In practice, approximately 10% of
vein segments were believed to be unsuitable; this was not
a common phenomenon. Patients who agree to participate
in a clinical trial may be more health-conscious and more
likely to comply with antiplatelet and cholesterol-lowering
medications, thereby influencing graft patency. Patients
who agree to return for study angiography may be further
self-selecting. However, the characteristics of the 120 pa-
tients returning for graft evaluation did not differ in any mea-
sured variable from the 31 who did not.
The patency rate was 93% in the small number of vein
grafts that were not randomized, suggesting that the good pa-
tency of randomized grafts was not related to selection of op-
timal targets. The patency rate of LITA grafts was 96%,
consistent with expectations for a 1-year assessment. Impor-
tantly, in 10 grafts in which a connector had initially been
implanted, but which had to be replaced with a second con-
nector or converted to a sutured anastomosis owing to tech-
nical issues, patency was 90%. Thus a failed or suboptimal
initial deployment of the device was not associated with re-
duced patency at 1 year. We did note, however, a 3% inci-
dence of stenosis at or near the device in the connector grafts.
One patient had an occipital stroke during follow-up cor-
onary angiography, as the LITA was being instrumented.
This event led to a decision by the data safety and monitor-
ing board to abandon any further conventional angiography
and switch to CT angiography and MRI to assess graft pa-
tency. Although the risk of stroke during angiography is
very low, its potential seriousness raises issues as to whether
conventional angiography continue to be the standard tech-
nique for future graft patency studies. Given the continuing
advances in CT angiography, this modality may become the
de facto standard for investigation.
The history of the St Jude Medical aortic connector sys-
tems illustrates the complexity of the clinical introduction
of new technology and the importance of controlled studies
when evaluating new technical equipment in medicine. Af-
ter promising feasibility studies with short periods of fol-
low-up without controls, the first-generation connector was
widely used and more than 40,000 implants were performed
worldwide. After some time, it became clear that there were
questionable issues with regard to graft patency with the
connector-made anastomosis, and users began to lose confi-
dence in the technology. Reported results with the first-gen-
eration device varied from excellent to poor. In addition toThe Journal of Thoracic and Cathe factors detailed above, it became clear that extreme
care was required during loading of the vein segments
onto the delivery system, and variability in this aspect may
also have contributed to the discrepant results. Ultimately,
owing to the emergence of drug-eluting stents and other fac-
tors, there was a decline in the volumes of CABG and a de-
creasing interest in OPCAB, which may have been the main
market for the device. The decrease in the market for the de-
vice led to St Jude Medical making the decision in Septem-
ber 2004 to discontinue manufacture and sales of the device.
Before that time, developmental work had resulted in the
second-generation device and the multicenter study that
had already been initiated.
In conclusion, this prospective multicenter randomized
controlled trial demonstrated good in-hospital and late clin-
ical outcomes and excellent 1-year patency for vein grafts
anastomosed both by the St Jude Medical second-generation
aortic connector system and by conventional suture tech-
niques. The patency of the connector grafts did not differ
from that of the hand-sutured grafts. Nonrandomized vein
grafts and LITA grafts also had excellent patency rates.
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Dr JohnW.Hammon, Jr (Winston-Salem, NC). This study was
a continued analysis of data that were presented at this meeting last
year. That study also showed that brain injury was magnified byrdiovascular Surgery c Volume 139, Number 3 745
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taining the patient at a hypothermic temperature, thus incriminating
rewarming in the injury profile of two different organ systems. For
the benefit of any perfusionists present and those of us who have
been studying this, I would like to ask you a couple of questions.
You mentioned that rate of rewarming has been shown to be im-
portant. Was rate of rewarming standard in your study or was it de-
termined by the perfusionist or the surgeon, and did you find any
correlation between rate of rewarming and renal injury?
Dr Boodhwani. Thank you very much for those positive com-
ments, Dr Hammon. The rate of rewarming was controlled only
by the fact that patients enrolled in this trial were relatively uniform.
They all underwent straightforward, nonemergency CABG sur-
gery. In those patients we examined the time period over which
the warming occurred, and typically it occurred over a period of
20 to 25 minutes. The temperature change in the rewarmed group
was from 32 C to 37 C. So that was approximately the rate of re-
warming. This was tracked in individual patients but specific corre-
lations for renal function were not performed.
Dr Hammon. The second question relates to the actual temper-
ature of the arterial blood entering the patient’s ascending aorta
through the perfusion cannula. In your manuscript you state that
the temperature was never allowed to rise above 37.5 C. First,
where exactly was that measured? Second, what was the water
bath temperature that the perfusionist set in the pump to achieve
that temperature? In many cases the water bath temperature is as
high as 39 C, which can have differential heating effects on the
blood.
Dr Boodhwani. The study protocol did not control exactly the
water bath temperature. It was controlling the oxygenator outlet
temperatures, though, and oxygenator outlet temperatures were re-
flective of the temperature at which the blood enters the patient’s
body. Those were never allowed to exceed 37.5 C in the normo-
thermic patients and 34.5 C in the patients assigned to mild hypo-
thermia.
Dr Hammon. I have one more question, and it is really more of
a hypothesis than anything else. This morning we heard in an off-
pump study that there is much more elaboration of myocardial en-
zymes in patients undergoing on-pump surgery than off-pump sur-
gery. Could it be elaborated as a hypothesis that one of the reasons
for this would be that the 3 organs in the body that get the most
blood flow during rewarming—the brain, the kidneys, and the
heart—have now been shown to manifest injury? At least 2 of
them have. Could this increased elaboration of enzymes from the
heart also be due to rewarming, and did you collect enzyme data
on your patients that you could study and confirm my humble hy-
pothesis?
Dr Boodhwani. That is actually a very insightful hypothesis.
We did collect cardiac enzyme data in these studies, and we found
that the normothermic patients had higher levels of creatinine ki-
nase. Troponin T levels were only measured in our cohort if the cre-
atinine kinase levels exceeded 800 mg/dL, and troponin levels in
fact were not significantly different in the study. Having said
that, the only additional thing that I would point out is that there
is a key difference between the heart and the other organs: obvi-
ously, the heart undergoes a definite period of ischemia and reper-
fusion, whereas the mechanisms of renal or brain injury that occurs
with cardiopulmonary bypass still remain to be clearly defined,746 The Journal of Thoracic and Cardiovascular Surgwhether it is an ischemic burden or an inflammatory injury.
Many hypotheses have been postulated, and we are still unclear
what the exact effect of temperature is on those mechanisms of in-
jury.
Dr Christina Mora-Mangano (Stanford, Calif). This is an el-
egant paper, and your group has done a number of important stud-
ies on temperature management and end organ dysfunction in
patients undergoing cardiac surgery. However, there are potential
problems regarding your definition of renal dysfunction. The ne-
phrology community has been challenged to agree on a definition
of renal dysfunction. The definition applied in this study differs
from that used by The Society of Thoracic Surgeons database
and is not consistent with definitions that we have used in some
of our work. In your report, 17% of the study patients had postop-
erative renal dysfunction; this is substantially greater than rates re-
ported in the majority of studies assessing perioperative renal
function. Most investigations suggest that 5% to 8% of cardiac sur-
gery patients will have an important compromise in renal function.
Can you address the issues regarding the definition of renal dys-
function? Additionally, in view of the ‘‘inclusive’’ definition of
dysfunction, was there a significant increase in the duration of hos-
pitalization for those patients characterized as having an adverse
renal event?
Dr Boodhwani. Thank you for those very good questions. You
are right. The definition of postoperative renal dysfunction is signif-
icantly debated in the literature. Older studies have used one of two
clinical measures, the first one being postoperative serum creatinine
levels and the second being estimated creatinine clearance using
a variety of different formulas. The incremental increase that con-
stitutes significant renal dysfunction is variable in the literature.
However, a common cutoff that has been used is 25%. A number
of studies have correlated this degree of renal dysfunction with
hard clinical end points of mortality, morbidity, as well as intensive
care unit and hospital stay.
As you mentioned, there was a recent consensus conference by
the Acute Dialysis Quality Initiative to more clearly define renal
dysfunction, and they came up essentially with 3 recommendations.
The first one was that calculated creatinine clearance or urinary pro-
tein measurement should not be used. The second recommendation
was that estimated creatinine clearance should be incorporated into
the definition, if possible. The third recommendation was that
change from baseline is a better indicator of renal dysfunction
than absolute values at any given point in the postoperative period.
We tried to incorporate all these aspects of the definition, and in fact
the risk factor and life expectancy criteria that were described in
that Acute Dialysis Quality Initiative report suggested that a 25%
reduction in estimated creatinine clearance would constitute mild
renal injury.
Having said that, we looked at our cohort and recognized that
this is a relatively low-risk population. Had we chosen a very strin-
gent definition of renal dysfunction, you are right, our renal dys-
function rates would have been much lower, but we probably
would have missed a clinically significant effect of the temperature
intervention. That is why we chose an end point that was fairly fre-
quent in our study population but met the criteria for clinical signif-
icance.
To answer the second part of your question, patients who had re-
nal dysfunction in our study did stay in the hospital an average of 2ery c March 2010
Wiklund et al Evolving Technology/Basic Sciencedays longer than the patients who did not. This has some impact on
clinical outcome.
Dr Mora-Mangano. I would like to make one more comment
about the question regarding the rate of rewarming after hypother-
mic cardiopulmonary bypass. I believe that we still lack the data to
assess the impact of the rate of warming on perioperative adverse
outcomes. Currently available studies should undergo careful scru-
tiny. In most reports, subjects in the rapid-rewarming group achieve
greater absolute temperatures than do those patients rewarmed
more slowly. Thus it is unclear as to whether or not we are assessing
and comparing the actual rewarming rate or the highest temperature
achieved in the study groups.
Dr Bruce B. Davis (Malvern, Australia). I have enjoyed your
work over the years. Your maximum blood temperature of
37.5C seems to be higher than what we would have used, and I
am not sure I picked up your incremental rate of warming. Can
you comment on that first?
Dr Boodhwani. As a pretext to these studies, we conducted
a survey of various Canadian centers looking at temperature prac-
tices and found that in some cases people exceed 37.5C. This sur-The Journal of Thoracic and Cavey was conducted in the 1990s, and perhaps that information is
a bit outdated. But about 30% of centers at that time were exceeding
temperatures of 38C.We believed at the time of the design of these
studies that 37.5C was a safe temperature to be the ceiling temper-
ature that we would permit in these trials.
Dr Davis. And the incremental rate of warming?
Dr Boodhwani. By that you mean the rate over which the tem-
perature changes?
Dr Davis. Yes.
Dr Boodhwani. In this study that occurred over a period of 20 to
25 minutes for a 5C change in temperature.
Dr Davis. Did you have any problems with postoperative and
intensive care, which we would have if we did not rewarm the pa-
tients? Were they intubated for much longer?
Dr Boodhwani. That is a great point. In the second study in
which sustained hypothermia was compared with normothermia,
there was in fact a trend toward sooner discharge from the intensive
care unit in the hypothermic patients. So actually there was no det-
rimental effect of hypothermia in terms of length of ventilation or
length of intensive care unit stay, bleeding, or infection rates.rdiovascular Surgery c Volume 139, Number 3 747
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